Hypothesis

We hypothesize that simultaneous pharmacological inhibition of PI3K‑AKT‑FOXO1 signaling and Wnt pathway activity, coupled with neutralization of tumor‑growth factor‑β (TGF‑β) secreted by maladaptive immune cells, will synergistically replenish the DIO2+ mature decidual stromal subpopulation (Str4) and reverse age‑associated endometrial senescence, fibrosis, and decidualization defects.

Rationale

• PI3K‑AKT‑FOXO1 overactivation drives stromal senescence and fibrosis in endometria from individuals >35 y, reducing FOXO1 nuclear activity and suppressing DIO2 transcription [1][3].
• CDC42 loss in stromal cells triggers premature senescence via Wnt pathway hyperactivation, blocking decidualization [2]; Wnt inhibition with XAV‑939 rescues this phenotype in vitro.
• Single‑cell atlases reveal that DIO2+ Str4 cells are depleted in implantation failure contexts, accompanied by a senescence‑associated secretory phenotype (SASP) [4][5]
• Immune‑stromal crosstalk in thin endometrium shows IGFBP3+ stromal repair cells are actively suppressed by pro‑fibrotic immune signals, notably TGF‑β [6]
• Endometrial stem‑cell exhaustion combined with senescence induction precedes implantation failure [7]

These data suggest that PI3K‑driven FOXO1 cytoplasmic sequestration, CDC42‑Wnt‑mediated senescence, and TGF‑β‑dependent immune inhibition converge to erase the DIO2+ stromal niche. Targeting only one axis (e.g., PI3K or Wnt) yields partial rescue, as shown by organoid experiments where LY294002 or 740Y‑P alone modulate but do not fully normalize decidual markers [1][2]. We propose that combined pathway blockade removes the upstream senescence trigger while TGF‑β neutralization alleviates the immune‑mediated block on stromal repair, permitting FOXO1 nuclear return, DIO2 re‑expression, and functional decidualization.

Experimental Design

In vitro

1. Generate endometrial stromal organoids from donors aged ≥ 38 y (representing the age‑associated dysfunction window) and from young donors (< 30 y) as controls.
2. Treat organoids for 72 h with:
   • Vehicle (DMSO)
   • LY294002 (PI3K inhibitor, 10 µM)
   • XAV‑939 (Wnt/β‑catenin inhibitor, 5 µM)
   • Anti‑TGF‑β neutralizing antibody (10 µg mL⁻¹)
   • Combination: LY294002 + XAV‑939
   • Combination: LY294002 + XAV‑939 + anti‑TGF‑β
3. Assess:
   • FOXO1 nuclear localization (immunofluorescence)
   • DIO2+ Str4 proportion (single‑cell RNA‑seq or flow cytometry for DIO2 protein)
   • Senescence (SA‑β‑gal activity, p16^INK4a^ mRNA)
   • Fibrosis (Collagen I α1 expression, hydroxyproline assay)
   • Decidualization response to cAMP + MPA (PRL, IGFBP1 secretion)

In vivo

• Use naturally aged (12‑month‑old) C57BL/6 mice; administer intra‑uterine injections of LY294002, XAV‑939, and anti‑TGF‑β (or IgG control) twice weekly for 2 weeks prior to mating.
• Quantify implantation sites, decidual zone thickness, and DIO2+ stromal cell density (immunohistochemistry).
• Compare pregnancy rates and litter size.

Expected Outcomes

• Dual PI3K/Wnt inhibition will partially increase DIO2+ cells and reduce senescence markers versus monotherapy.
• Addition of TGF‑β neutralization will produce a synergistic effect: ≥ 2‑fold rise in DIO2+ Str4 fraction, significant ↓ in SA‑β‑gal and Collagen I, and restoration of decidual hormone secretion to levels comparable with young controls.
• In aged mice, the triple treatment will rescue implantation site number and decidual thickness, yielding pregnancy rates not significantly different from young controls.

Potential Pitfalls and Alternatives

• Off‑target effects of LY294002 or XAV‑939 may affect epithelial cells; using stromal‑specific Cre‑loxP drug delivery (e.g., Pdgfrb‑CreERT2) could mitigate this.
• Redundant Wnt ligands might sustain β‑catenin activity; testing a PORCN inhibitor (blocks Wnt secretion) as an alternative to XAV‑939 could be considered.
• TGF‑β has homeostatic roles; transient, localized blockade (e.g., hydrogel‑based intra‑uterine release) may limit systemic side effects.

Falsifiability: If the triple therapy fails to increase DIO2+ Str4 cells or improve decidualization beyond the effects of dual PI3K/Wnt inhibition alone (p > 0.05, ANOVA with post‑hoc Tukey), the hypothesis is refuted. Conversely, a statistically significant synergistic improvement supports the mechanistic model of convergent PI3K‑Wnt‑TGF‑β signaling driving age‑related loss of functional decidual stromal cells.